Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Kairos Pharma Ltd. (NYSE: KAPA) announced interim results from its Phase 2 clinical trial for ENV-105, showing a statistically significant improvement in progression-free survival for patients with metastatic castration-resistant prostate cancer. Patients receiving the ENV-105 combination achieved a median progression-free survival of 17.7 months compared to 2 months for those on apalutamide alone. Following these results, the company modified its trial protocol to recruit patients earlier in disease progression and aims to complete the study by Q4 2027. However, KAPA shares fell 22.58% to $1.20, marking a new 52-week low.